T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

Clinical Immunology

Volumn 149, Issue 3 PB, 2013, Pages 534-555

  Jawa, Vibha ^a   Cousens, Leslie P ^a   Awwad, Michel ^a   Wakshull, Eric ^a   Kropshofer, Harald ^a   De Groot, Anne S ^a,b  

^a University of Rhode Island ^*

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Cell mediated immunity; Immunogenicity; ; Quality by Design; ; T cell;

Indexed keywords

BIOLOGICAL PRODUCT; BLOOD CLOTTING FACTOR 8 INHIBITOR; CETUXIMAB; CYCLOPHOSPHAMIDE; DRUG ANTIBODY; EPITOPE; IMMUNOLOGIC AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; RECOMBINANT BETA INTERFERON; RECOMBINANT PROTEIN; RITUXIMAB; TETRAMER; VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; BINDING AFFINITY; BINDING ASSAY; BINDING COMPETITION; BIOLOGICAL THERAPY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG STABILITY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; ENZYME REPLACEMENT; EPITOPE MAPPING; GENE REPLACEMENT THERAPY; HLA SYSTEM; HLA TYPING; HUMAN; IC 50; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MULTIPLE SCLEROSIS; NONHUMAN; PHARMACODYNAMICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 84888022850     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.09.006     Document Type: Review

References (199)

1. Dimitrov D.S. Therapeutic proteins. Methods Mol. Biol. 2012, 899:1-26.
2. Strohl W.R., Knight D.M. Discovery and development of biopharmaceuticals: current issues. Curr. Opin. Biotechnol. 2009, 20:668-672.
3. Walsh G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 2010, 28:917-924.
4. Barbosa M.D. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. Drug Discov. Today 2011, 16:345-353.
5. Eckardt K.U., Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol. Dial. Transplant. 2003, 18:865-869.
6. Tatarewicz S.M., Wei X., Gupta S., Masterman D., Swanson S.J., Moxness M.S. Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J. Clin. Immunol. 2007, 27:620-627.
7. Jawa V., Hokom M., Hu Z., El-Abaadi N., Zhuang Y., Berger D., Gupta S., Swanson S.J., Chirmule N. Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects. Ann. Hematol. 2010, 89:S75-S85.
8. Shankar G., Pendley C., Stein K.E. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 2007, 25:555-561.
9. Sauerborn M., van de Vosse E., Delawi D., van Dissel J.T., Brinks V., Schellekens H. Natural antibodies against bone morphogenic proteins and interferons in healthy donors and in patients with infections linked to type-1 cytokine responses. J. Interferon Cytokine Res. 2011, 31:661-669.
10. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.J., Martin-Dupont P., Michaud P., Papo T., Ugo V., Teyssandier I., Varet B., Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 2002, 346:469-475.
11. Li J., Yang C., Xia Y., Bertino A., Glaspy J., Roberts M., Kuter D.J. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98:3241-3248.
12. Baert F., Noman M., Vermeire S., Van Assche G., D.H.G., Carbonez A., Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 2003, 348:601-608.
13. Chung C.H., Mirakhur B., Chan E., Le Q.T., Berlin J., Morse M., Murphy B.A., Satinover S.M., Hosen J., Mauro D., Slebos R.J., Zhou Q., Gold D., Hatley T., Hicklin D.J., Platts-Mills T.A. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N. Engl. J. Med. 2008, 358:1109-1117.
14. Singh S.K. Impact of product-related factors on immunogenicity of biotherapeutics. J. Pharm. Sci. 2011, 100:354-387.
15. Gutierrez A.H., Moise L., De Groot A.S. Of [hamsters] and men: a new perspective on host cell proteins. Hum. Vaccin. Immunother. 2012, 8.
16. Lewis K. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B 2012, Inspiration Biopharmaceuticals.
17. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins EMEA/CHMP/BMWP/14327/2007 2007, E.M. Agency (Ed.).
18. Monzavi-Karbassi B., Shamloo S., Kieber-Emmons M., Jousheghany F., Luo P., Lin K.Y., Cunto-Amesty G., Weiner D.B., Kieber-Emmons T. Priming characteristics of peptide mimotopes of carbohydrate antigens. Vaccine 2003, 21:753-760.
19. Beck A., Wagner-Rousset E., Bussat M.C., Lokteff M., Klinguer-Hamour C., Haeuw J.F., Goetsch L., Wurch T., Van Dorsselaer A., Corvaia N. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr. Pharm. Biotechnol. 2008, 9:482-501.
20. Mueller R., Karle A., Vogt A., Kropshofer H., Ross A., Maeder K., Mahler H.C. Evaluation of the immuno-stimulatory potential of stopper extractables and leachables by using dendritic cells as readout. J. Pharm. Sci. 2009, 98:3548-3561.
21. Rosenberg A.S. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006, 8:E501-E507.
22. Buttel I.C., Chamberlain P., Chowers Y., Ehmann F., Greinacher A., Jefferis R., Kramer D., Kropshofer H., Lloyd P., Lubiniecki A., Krause R., Mire-Sluis A., Platts-Mills T., Ragheb J.A., Reipert B.M., Schellekens H., Seitz R., Stas P., Subramanyam M., Thorpe R., Trouvin J.H., Weise M., Windisch J., Schneider C.K. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 2011, 39:100-109.
23. Joubert M.K., Hokom M., Eakin C., Zhou L., Deshpande M., Baker M.P., Goletz T.J., Kerwin B.A., Chirmule N., Narhi L.O., Jawa V. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J. Biol. Chem. 2012, 287:25266-25279.
24. Joubert M.K., Luo Q., Nashed-Samuel Y., Wypych J., Narhi L.O. Classification and characterization of therapeutic antibody aggregates. J. Biol. Chem. 2011, 286:25118-25133.
25. Verthelyi D., Wang V. Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins. PLoS One 2010, 5:e15252.
26. van Beers M.M., Jiskoot W., Schellekens H. On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. J. Interferon Cytokine Res. 2010, 30:767-775.
27. Rathore A.S., Winkle H. Quality by design for biopharmaceuticals. Nat. Biotechnol. 2009, 27:26-34.
28. Praditpornsilpa K., Kupatawintu P., Mongkonsritagoon W., Supasyndh O., Jootar S., Intarakumthornchai T., Pongskul C., Prasithsirikul W., Achavanuntakul B., Ruangkarnchanasetr P., Laohavinij S., Eiam-Ong S. The association of anti-r-HuEpo-associated pure red cell aplasia with HLA-DRB1*09-DQB1*0309. Nephrol. Dial. Transplant. 2009, 24:1545-1549.
29. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., Koren E., Liu H., Maia M., Parish T., Scott G., Shankar G., Shores E., Swanson S.J., Taniguchi G., Wierda D., Zuckerman L.A. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 2004, 289:1-16.
30. Gupta S., Indelicato S.R., Jethwa V., Kawabata T., Kelley M., Mire-Sluis A.R., Richards S.M., Rup B., Shores E., Swanson S.J., Wakshull E. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods 2007, 321:1-18.
31. Koren E., Smith H.W., Shores E., Shankar G., Finco-Kent D., Rup B., Barrett Y.C., Devanarayan V., Gorovits B., Gupta S., Parish T., Quarmby V., Moxness M., Swanson S.J., Taniguchi G., Zuckerman L.A., Stebbins C.C., Mire-Sluis A. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 2008, 333:1-9.
32. Shankar G., Devanarayan V., Amaravadi L., Barrett Y.C., Bowsher R., Finco-Kent D., Fiscella M., Gorovits B., Kirschner S., Moxness M., Parish T., Quarmby V., Smith H., Smith W., Zuckerman L.A., Koren E. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 2008, 48:1267-1281.
33. Assay development for immunogenicity testing of therapeutic proteins 2009, U.F.C. CBER (Ed.).
34. Stickler M., Rochanayon N., Razo O.J., Mucha J., Gebel W., Faravashi N., Chin R., Holmes S., Harding F.A. An in vitro human cell-based assay to rank the relative immunogenicity of proteins. Toxicol. Sci. 2004, 77:280-289.
35. De Groot A.S., Scott D.W. Immunogenicity of protein therapeutics. Trends Immunol. 2007, 28:482-490.
36. De Groot A.S., McMurry J., Moise L. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr. Opin. Pharmacol. 2008, 8:620-626.
37. Perry L.C., Jones T.D., Baker M.P. New approaches to prediction of immune responses to therapeutic proteins during preclinical development. Drugs R D 2008, 9:385-396.
38. Stas P., Lasters I. Strategies for preclinical immunogenicity assessment of protein therapeutics. IDrugs 2009, 12:169-173.
39. Harding F.A., Stickler M.M., Razo J., DuBridge R.B. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2010, 2:256-265.
40. Wullner D., Zhou L., Bramhall E., Kuck A., Goletz T.J., Swanson S., Chirmule N., Jawa V. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin. Immunol. 2010, 137:5-14.
41. De Groot A.S., Moise L., McMurry J.A., Wambre E., Van Overtvelt L., Moingeon P., Scott D.W., Martin W. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 2008, 112:3303-3311.
42. Bryson C.J., Jones T.D., Baker M.P. Prediction of immunogenicity of therapeutic proteins: validity of computational tools. BioDrugs 2010, 24:1-8.
43. Honeyman M.C., Stone N.L., Falk B.A., Nepom G., Harrison L.C. Evidence for molecular mimicry between human T cell epitopes in rotavirus and pancreatic islet autoantigens. J. Immunol. 2010, 184:2204-2210.
44. Cusick M.F., Libbey J.E., Fujinami R.S. Molecular mimicry as a mechanism of autoimmune disease. Clin. Rev. Allergy Immunol. 2012, 42(1):102-111.
45. Siliciano R.F., Keegan A.D., Dintzis R.Z., Dintzis H.M., Shin H.S. The interaction of nominal antigen with T cell antigen receptors. I. Specific binding of multivalent nominal antigen to cytolytic T cell clones. J. Immunol. 1985, 135:906-914.
46. Zubler R.H. Naive and memory B cells in T-cell-dependent and T-independent responses. Springer Semin. Immunopathol. 2001, 23:405-419.
47. Goodnow C.C., Vinuesa C.G., Randall K.L., Mackay F., Brink R. Control systems and decision making for antibody production. Nat. Immunol. 2010, 11:681-688.
48. Onda M. Reducing the immunogenicity of protein therapeutics. Curr. Drug Targets 2009, 10:131-139.
49. Defrance T., Taillardet M., Genestier L. T cell-independent B cell memory. Curr. Opin. Immunol. 2011, 23:330-336.
50. Weaver J.M., Lazarski C.A., Richards K.A., Chaves F.A., Jenks S.A., Menges P.R., Sant A.J. Immunodominance of CD4 T cells to foreign antigens is peptide intrinsic and independent of molecular context: implications for vaccine design. J. Immunol. 2008, 181:3039-3048.
51. Moxness M., Tatarewicz S., Weeraratne D., Murakami N., Wullner D., Mytych D., Jawa V., Koren E., Swanson S.J. Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin. Chem. 2005, 51:1983-1985.
52. Tangri S., Mothe B.R., Eisenbraun J., Sidney J., Southwood S., Briggs K., Zinckgraf J., Bilsel P., Newman M., Chesnut R., Licalsi C., Sette A. Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol. 2005, 174:3187-3196.
53. Barbosa M.D., Vielmetter J., Chu S., Smith D.D., Jacinto J. Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin. Immunol. 2006, 118:42-50.
54. Koren E., De Groot A.S., Jawa V., Beck K.D., Boone T., Rivera D., Li L., Mytych D., Koscec M., Weeraratne D., Swanson S., Martin W. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin. Immunol. 2007, 124:26-32.
55. Pratt K.P., Thompson A.R. B-cell and T-cell epitopes in anti-factor VIII immune responses. Clin. Rev. Allergy Immunol. 2009, 37:80-95.
56. Kamate C., Lenting P.J., van den Berg H.M., Mutis T. Depletion of CD4+/CD25high regulatory T cells may enhance or uncover factor VIII-specific T-cell responses in healthy individuals. J. Thromb. Haemost. 2007, 5:611-613.
57. Yarkoni S., Kaminitz A., Sagiv Y., Yaniv I., Askenasy N. Involvement of IL-2 in homeostasis of regulatory T cells: the IL-2 cycle. Bioessays 2008, 30:875-888.
58. Bluestone J.A., Abbas A.K. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 2003, 3:253-257.
59. Tsuji N.M., Kosaka A. Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells. Trends Immunol. 2008, 29:532-540.
60. Eyerman M.C., Zhang X., Wysocki L.J. T cell recognition and tolerance of antibody diversity. J. Immunol. 1996, 157:1037-1046.
61. Umetsu D.T., DeKruyff R.H. The regulation of allergy and asthma. Immunol. Rev. 2006, 212:238-255.
62. Karlsson M.R., Rugtveit J., Brandtzaeg P. Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy. J. Exp. Med. 2004, 199:1679-1688.
63. Kendal A.R., Chen Y., Regateiro F.S., Ma J., Adams E., Cobbold S.P., Hori S., Waldmann H. Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance. J. Exp. Med. 2011, 208:2043-2053.
64. Congia M., Patel S., Cope A.P., De Virgiliis S., Sonderstrup G. T cell epitopes of insulin defined in HLA-DR4 transgenic mice are derived from preproinsulin and proinsulin. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:3833-3838.
65. Farrell R.J., Alsahli M., Jeen Y.T., Falchuk K.R., Peppercorn M.A., Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003, 124:917-924.
66. Rohrbach M., Klein A., Kohli-Wiesner A., Veraguth D., Scheer I., Balmer C., Lauener R., Baumgartner M.R. CRIM-negative infantile Pompe disease: 42-month treatment outcome. J. Inherit. Metab. Dis. 2010, 33:751-757.
67. Moran E., Carbone F., Augusti V., Patrone F., Ballestrero A., Nencioni A. Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience. Semin. Hematol. 2012, 49:270-276.
68. Joseph A., Neff K., Richard J., Gao L., Bangari D., Joly M., Culm-Merdek K., Garman R., Williams J., Richards S., Ruzek M. Transient low-dose methotrexate induces tolerance to murine anti-thymocyte globulin and together they promote long-term allograft survival. J. Immunol. 2012, 189:732-743.
69. Kim Y., Sette A., Peters B. Applications for T-cell epitope queries and tools in the Immune Epitope Database and Analysis Resource. J. Immunol. Methods 2011, 374(1-2):62-69.
70. Godkin A.J., Smith K.J., Willis A., Tejada-Simon M.V., Zhang J., Elliott T., Hill A.V. Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions. J. Immunol. 2001, 166:6720-6727.
71. Doytchinova I.A., Walshe V.A., Jones N.A., Gloster S.E., Borrow P., Flower D.R. Coupling in silico and in vitro analysis of peptide-MHC binding: a bioinformatic approach enabling prediction of superbinding peptides and anchorless epitopes. J. Immunol. 2004, 172:7495-7502.
72. De Groot A.S., Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin. Immunol. 2009, 131:189-201.
73. El-Manzalawy Y., Dobbs D., Honavar V. Predicting MHC-II binding affinity using multiple instance regression. IEEE/ACM Trans. Comput. Biol. Bioinform. 2011, 8(4):1067-1079.
74. Sette A., Buus S., Appella E., Smith J.A., Chesnut R., Miles C., Colon S.M., Grey H.M. Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:3296-3300.
75. De Groot A.S., Rayner J., Martin W. Modelling the immunogenicity of therapeutic proteins using T cell epitope mapping. Dev. Biol. (Basel) 2003, 112:71-80.
76. De Groot A.S., Berzofsky J.A. From genome to vaccine-new immunoinformatics tools for vaccine design. Methods 2004, 34:425-428.
77. Zhang G.L., Petrovsky N., Kwoh C.K., August J.T., Brusic V. PRED(TAP): a system for prediction of peptide binding to the human transporter associated with antigen processing. Immunome Res. 2006, 2:3.
78. Tong J.C., Zhang Z.H., August J.T., Brusic V., Tan T.W., Ranganathan S. In silico characterization of immunogenic epitopes presented by HLA-Cw*0401. Immunome Res. 2007, 3:7.
79. Zhang G.L., Khan A.M., Srinivasan K.N., Heiny A., Lee K., Kwoh C.K., August J.T., Brusic V. Hotspot Hunter: a computational system for large-scale screening and selection of candidate immunological hotspots in pathogen proteomes. BMC Bioinforma. 2008, 9(Suppl. 1):S19.
80. Flower D.R., Phadwal K., Macdonald I.K., Coveney P.V., Davies M.N., Wan S. T-cell epitope prediction and immune complex simulation using molecular dynamics: state of the art and persisting challenges. Immunome Res. 2010, 6(Suppl. 2):S4.
81. Sturniolo T., Bono E., Ding J., Raddrizzani L., Tuereci O., Sahin U., Braxenthaler M., Gallazzi F., Protti M.P., Sinigaglia F., Hammer J. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat. Biotechnol. 1999, 17:555-561.
82. Southwood S., Sidney J., Kondo A., del Guercio M.F., Appella E., Hoffman S., Kubo R.T., Chesnut R.W., Grey H.M., Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 1998, 160:3363-3373.
83. Valmori D., Levy F., Godefroy E., Scotto L., Souleimanian N.E., Karbach J., Tosello V., Hesdorffer C.S., Old L.J., Jager E., Ayyoub M. Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen. Clin. Immunol. 2007, 122:163-172.
84. Bond K.B., Sriwanthana B., Hodge T.W., De Groot A.S., Mastro T.D., Young N.L., Promadej N., Altman J.D., Limpakarnjanarat K., McNicholl J.M. An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1-infected Thais. AIDS Res. Hum. Retroviruses 2001, 17:703-717.
85. De Groot A.S., Bosma A., Chinai N., Frost J., Jesdale B.M., Gonzalez M.A., Martin W., Saint-Aubin C. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 2001, 19:4385-4395.
86. Dong Y., Demaria S., Sun X., Santori F.R., Jesdale B.M., De Groot A.S., Rom W.N., Bushkin Y. HLA-A2-restricted CD8+-cytotoxic-T-cell responses to novel epitopes in Mycobacterium tuberculosis superoxide dismutase, alanine dehydrogenase, and glutamine synthetase. Infect. Immun. 2004, 72:2412-2415.
87. McMurry J., Sbai H., Gennaro M.L., Carter E.J., Martin W., De Groot A.S. Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. Tuberculosis (Edinb.) 2005, 85:95-105.
88. Koita O.A., Dabitao D., Mahamadou I., Tall M., Dao S., Tounkara A., Guiteye H., Noumsi C., Thiero O., Kone M., Rivera D., McMurry J.A., Martin W., De Groot A.S. Confirmation of immunogenic consensus sequence HIV-1 T-cell epitopes in Bamako, Mali and Providence, Rhode Island. Hum. Vaccin. 2006, 2:119-128.
89. Cohen T., Moise L., Ardito M., Martin W., De Groot A.S. A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: individualized T cell epitope measure (iTEM). J. Biomed. Biotechnol. 2010, 2010.
90. Moise L., Buller R.M., Schriewer J., Lee J., Frey S.E., Weiner D.B., Martin W., De Groot A.S. VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Vaccine 2011, 29(3):501-511.
91. Ahlers J.D., Belyakov I.M., Thomas E.K., Berzofsky J.A. High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. J. Clin. Invest. 2001, 108:1677-1685.
92. De Groot A.S., Martin W. From immunome to vaccine: epitope mapping and vaccine design tools. Novartis Found. Symp. 2003, 254:57-72. (discussion 72-56, 98-101, 250-102).
93. De Groot A.S., Rivera D.S., McMurry J.A., Buus S., Martin W. Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV. Vaccine 2008, 26:3059-3071.
94. De Groot A.S., Ardito M., McClaine E.M., Moise L., Martin W.D. Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine. Vaccine 2009, 27:5740-5747.
95. Inaba H., Martin W., De Groot A.S., Qin S., De Groot L.J. Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' disease. J. Clin. Endocrinol. Metab. 2006, 91:2286-2294.
96. Weber C.A., Mehta P.J., Ardito M., Moise L., Martin B., De Groot A.S. T cell epitope: friend or foe? Immunogenicity of biologics in context. Adv. Drug Deliv. Rev. 2009, 61:965-976.
97. Moise L., Song C., Martin W.D., Tassone R., De Groot A.S., Scott D.W. Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. Clin. Immunol. 2012, 142:320-331.
98. Nielsen M., Lund O. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinforma. 2009, 10:296.
99. Rammensee H.G. Antigen presentation-recent developments. Int. Arch. Allergy Immunol. 1996, 110:299-307.
100. Fooksman D.R., Gronvall G.K., Tang Q., Edidin M. Clustering class I MHC modulates sensitivity of T cell recognition. J. Immunol. 2006, 176:6673-6680.
101. Sant A.J., Chaves F.A., Jenks S.A., Richards K.A., Menges P., Weaver J.M., Lazarski C.A. The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II:peptide complexes. Immunol. Rev. 2005, 207:261-278.
102. Kuttler C., Nussbaum A.K., Dick T.P., Rammensee H.G., Schild H., Hadeler K.P. An algorithm for the prediction of proteasomal cleavages. J. Mol. Biol. 2000, 298:417-429.
103. Kropshofer H., Singer T. Overview of cell-based tools for pre-clinical assessment of immunogenicity of biotherapeutics. J. Immunotoxicol. 2006, 3:131-136.
104. Rohn T.A., Reitz A., Paschen A., Nguyen X.D., Schadendorf D., Vogt A.B., Kropshofer H. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope. Cancer Res. 2005, 65:10068-10078.
105. Chicz R.M., Urban R.G. Analysis of MHC-presented peptides: applications in autoimmunity and vaccine development. Immunol. Today 1994, 15:155-160.
106. Lazarski C.A., Chaves F.A., Jenks S.A., Wu S., Richards K.A., Weaver J.M., Sant A.J. The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity 2005, 23:29-40.
107. Berer K., Krishnamoorthy G. Commensal gut flora and brain autoimmunity: a love or hate affair?. Acta Neuropathol. 2012, 123:639-651.
108. Welsh R.M., Che J.W., Brehm M.A., Selin L.K. Heterologous immunity between viruses. Immunol. Rev. 2010, 235:244-266.
109. Wang P., Sidney J., Dow C., Mothe B., Sette A., Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput. Biol. 2008, 4:e1000048.
110. Trouw L.A., Huizinga T.W., Toes R.E. Autoimmunity in rheumatoid arthritis: different antigens-common principles. Ann. Rheum. Dis. 2013, 72(Suppl. 2):ii132-ii136.
111. Kessler J.H., Benckhuijsen W.E., Mutis T., Melief C.J., van der Burg S.H., Drijfhout J.W. Competition-based cellular peptide binding assay for HLA class I. Curr. Protoc. Immunol. 2004, (Chapter 18, Unit 18 12).
112. Kessler J.H., Mommaas B., Mutis T., Huijbers I., Vissers D., Benckhuijsen W.E., Schreuder G.M., Offringa R., Goulmy E., Melief C.J., van der Burg S.H., Drijfhout J.W. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. Hum. Immunol. 2003, 64:245-255.
113. Steere A.C., Klitz W., Drouin E.E., Falk B.A., Kwok W.W., Nepom G.T., Baxter-Lowe L.A. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J. Exp. Med. 2006, 203:961-971.
114. McMurry J.A., Gregory S.H., Moise L., Rivera D., Buus S., De Groot A.S. Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. Vaccine 2007, 25:3179-3191.
115. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22:3099-3108.
116. Justesen S., Harndahl M., Lamberth K., Nielsen L.L., Buus S. Functional recombinant MHC class II molecules and high-throughput peptide-binding assays. Immunome Res. 2009, 5:2.
117. Buchli R., VanGundy R.S., Hickman-Miller H.D., Giberson C.F., Bardet W., Hildebrand W.H. Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLA-A*0201-a new tool for epitope discovery. Biochemistry 2005, 44:12491-12507.
118. Wu L.C., Tuot D.S., Lyons D.S., Garcia K.C., Davis M.M. Two-step binding mechanism for T-cell receptor recognition of peptide MHC. Nature 2002, 418:552-556.
119. Chang S.T., Ghosh D., Kirschner D.E., Linderman J.J. Peptide length-based prediction of peptide-MHC class II binding. Bioinformatics 2006, 22:2761-2767.
120. Guidance for industry: immunogenicity assessment for therapeutic protein products. DHHS FDA Docket No. FDA-2013-D-0092, Document No. 2013-03019 2013, (https://federalregister.gov/a/2013-03019).
121. Baker M.P., Jones T.D. Identification and removal of immunogenicity in therapeutic proteins. Curr. Opin. Drug Discov. Devel. 2007, 10:219-227.
122. Findlay L., Eastwood D., Ball C., Robinson C.J., Bird C., Wadhwa M., Thorpe S.J., Thorpe R., Stebbings R., Poole S. Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy. J. Immunol. Methods 2011, 371:134-142.
123. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 2006, 355:1018-1028.
124. Czerkinsky C., Andersson G., Ekre H.P., Nilsson L.A., Klareskog L., Ouchterlony O. Reverse ELISpot assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J. Immunol. Methods 1988, 110:29-36.
125. Czerkinsky C.C., Nilsson L.A., Nygren H., Ouchterlony O., Tarkowski A. A solid-phase enzyme-linked immunospot (ELISpot) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods 1983, 65:109-121.
126. Carson R.T., Vignali D.A. Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. J. Immunol. Methods 1999, 227:41-52.
127. Makitalo B., Andersson M., Arestrom I., Karlen K., Villinger F., Ansari A., Paulie S., Thorstensson R., Ahlborg N. ELISpot and ELISA analysis of spontaneous, mitogen-induced and antigen-specific cytokine production in cynomolgus and rhesus macaques. J. Immunol. Methods 2002, 270:85-97.
128. Basu R., Hatton R.D., Weaver C.T. The Th17 family: flexibility follows function. Immunol. Rev. 2013, 252:89-103.
129. Foster B., Prussin C., Liu F., Whitmire J.K., Whitton J.L. Detection of intracellular cytokines by flow cytometry. Curr. Protoc. Immunol. 2007, John Wiley and Sons, (Chapter 6; Unit 6.24).
130. Pala P., Hussell T., Openshaw P.J. Flow cytometric measurement of intracellular cytokines. J. Immunol. Methods 2000, 243:107-124.
131. Wooldridge L., Lissina A., Cole D.K., van den Berg H.A., Price D.A., Sewell A.K. Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology 2009, 126:147-164.
132. Jaber A., Baker M. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. J. Pharm. Biomed. Anal. 2007, 43:1256-1261.
133. Stickler M.M., Estell D.A., Harding F.A. CD4+ T-cell epitope determination using unexposed human donor peripheral blood mononuclear cells. J. Immunother. 2000, 23:654-660.
134. Delluc S., Ravot G., Maillere B. Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential. Blood 2010, 116:4542-4545.
135. Higbee R.G., Byers A.M., Dhir V., Drake D., Fahlenkamp H.G., Gangur J., Kachurin A., Kachurina O., Leistritz D., Ma Y., Mehta R., Mishkin E., Moser J., Mosquera L., Nguyen M., Parkhill R., Pawar S., Poisson L., Sanchez-Schmitz G., Schanen B., Singh I., Song H., Tapia T., Warren W., Wittman V. An immunologic model for rapid vaccine assessment - a clinical trial in a test tube. Altern. Lab. Anim. 2009, 37(Suppl. 1):19-27.
136. Giese C., Lubitz A., Demmler C.D., Reuschel J., Bergner K., Marx U. Immunological substance testing on human lymphatic micro-organoids in vitro. J. Biotechnol. 2010, 148:38-45.
137. Ma Y., Poisson L., Sanchez-Schmitz G., Pawar S., Qu C., Randolph G.J., Warren W.L., Mishkin E.M., Higbee R.G. Assessing the immunopotency of Toll-like receptor agonists in an in vitro tissue-engineered immunological model. Immunology 2010, 130:374-387.
138. Qu C., Nguyen V.A., Merad M., Randolph G.J. MHC class I/peptide transfer between dendritic cells overcomes poor cross-presentation by monocyte-derived APCs that engulf dying cells. J. Immunol. 2009, 182:3650-3659.
139. Schanen B.C., De Groot A.S., Moise L., Ardito M., McClaine E., Martin W., Wittman V., Warren W.L., Drake D.R. Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4(+) T cells against the swine-origin H1N1 influenza virus. Vaccine 2011, 29:3299-3309.
140. Dhir V., Fort M., Mahmood A., Higbee R., Warren W., Narayanan P., Wittman V. A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies. J. Immunotoxicol. 2012, 9(1):34-42.
141. Giese C., Demmler C.D., Ammer R., Hartmann S., Lubitz A., Miller L., Muller R., Marx U. A human lymph node in vitro-challenges and progress. Artif. Organs 2006, 30:803-808.
142. Moser J.M., Sassano E.R., Leistritz del C., Eatrides J.M., Phogat S., Koff W., Drake D.R. Optimization of a dendritic cell-based assay for the in vitro priming of naive human CD4+ T cells. J. Immunol. Methods 2010, 353:8-19.
143. Subbramanian R.A., Basha S., Brady R.C., Hazenfeld S., Shata M.T., Bernstein D.I. Age-related changes in magnitude and diversity of cross-reactive CD4+ T-cell responses to the novel pandemic H1N1 influenza hemagglutinin. Hum. Immunol. 2010, 71:957-963.
144. Karasuyama H., Mukai K., Tsujimura Y., Obata K. Newly discovered roles for basophils: a neglected minority gains new respect. Nat. Rev. Immunol. 2009, 9:9-13.
145. Davis M.M., Altman J.D., Newell E.W. Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis. Nat. Rev. Immunol. 2011, 11:551-558.
146. Maecker H.T., McCoy J.P., Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat. Rev. Immunol. 2012, 12:191-200.
147. Pan S., Trejo T., Hansen J., Smart M., David C.S. HLA-DR4 (DRB1*0401) transgenic mice expressing an altered CD4-binding site: specificity and magnitude of DR4-restricted T cell response. J. Immunol. 1998, 161:2925-2929.
148. Kong Y.C., Lomo L.C., Motte R.W., Giraldo A.A., Baisch J., Strauss G., Hammerling G.J., David C.S. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene. J. Exp. Med. 1996, 184:1167-1172.
149. Shirai M., Arichi T., Nishioka M., Nomura T., Ikeda K., Kawanishi K., Engelhard V.H., Feinstone S.M., Berzofsky J.A. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J. Immunol. 1995, 154:2733-2742.
150. Le A.X., Bernhard E.J., Holterman M.J., Strub S., Parham P., Lacy E., Engelhard V.H. Cytotoxic T cell responses in HLA-A2.1 transgenic mice. Recognition of HLA alloantigens and utilization of HLA-A2.1 as a restriction element. J. Immunol. 1989, 142:1366-1371.
151. Didierlaurent A., Ramirez J.C., Gherardi M., Zimmerli S.C., Graf M., Orbea H.A., Pantaleo G., Wagner R., Esteban M., Kraehenbuhl J.P., Sirard J.C. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. Vaccine 2004, 22:3395-3403.
152. Man S., Newberg M.H., Crotzer V.L., Luckey C.J., Williams N.S., Chen Y., Huczko E.L., Ridge J.P., Engelhard V.H. Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice. Int. Immunol. 1995, 7:597-605.
153. Charo J., Sundback M., Geluk A., Ottenhoff T., Kiessling R. DNA immunization of HLA transgenic mice with a plasmid expressing mycobacterial heat shock protein 65 results in HLA class I- and II-restricted T cell responses that can be augmented by cytokines. Hum. Gene Ther. 2001, 12:1797-1804.
154. Ishioka G.Y., Fikes J., Hermanson G., Livingston B., Crimi C., Qin M., del Guercio M.F., Oseroff C., Dahlberg C., Alexander J., Chesnut R.W., Sette A. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J. Immunol. 1999, 162:3915-3925.
155. Livingston B.D., Newman M., Crimi C., McKinney D., Chesnut R., Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 2001, 19:4652-4660.
156. Hanke T., McMichael A.J., Mwau M., Wee E.G., Ceberej I., Patel S., Sutton J., Tomlinson M., Samuel R.V. Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine 2002, 20:1995-1998.
157. Ragni M.V., Bontempo F.A., Lewis J.H. Disappearance of inhibitor to factor VIII in HIV-infected hemophiliacs with progression to AIDS or severe ARC. Transfusion 1989, 29:447-449.
158. Clark E.A., Ledbetter J.A. How B and T cells talk to each other. Nature 1994, 367:425-428.
159. Reipert B.M., Sasgary M., Ahmad R.U., Auer W., Turecek P.L., Schwarz H.P. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance. Thromb. Haemost. 2001, 86:1345-1352.
160. Holder M.J., Wang H., Milner A.E., Casamayor M., Armitage R., Spriggs M.K., Fanslow W.C., MacLennan I.C., Gregory C.D., Gordon J., et al. Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bc1-2 induction. Eur. J. Immunol. 1993, 23:2368-2371.
161. Klaus G.G., Choi M.S., Lam E.W., Johnson-Leger C., Cliff J. CD40: a pivotal receptor in the determination of life/death decisions in B lymphocytes. Int. Rev. Immunol. 1997, 15:5-31.
162. Qian J., Burkly L.C., Smith E.P., Ferrant J.L., Hoyer L.W., Scott D.W., Haudenschild C.C. Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer. Eur. J. Immunol. 2000, 30:2548-2554.
163. Bi L., Lawler A.M., Antonarakis S.E., High K.A., Gearhart J.D., Kazazian H.H. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat. Genet. 1995, 10:119-121.
164. Mangalam A., Rodriguez M., David C. A new humanized HLA transgenic mouse model of multiple sclerosis expressing class II on mouse CD4 T cells. Ann. N. Y. Acad. Sci. 2007, 1103:112-117.
165. Brehm M.A., Cuthbert A., Yang C., Miller D.M., DiIorio P., Laning J., Burzenski L., Gott B., Foreman O., Kavirayani A., Herlihy M., Rossini A.A., Shultz L.D., Greiner D.L. Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin. Immunol. 2010, 135:84-98.
166. Ishikawa F., Saito Y., Yoshida S., Harada M., Shultz L.D. The differentiative and regenerative properties of human hematopoietic stem/progenitor cells in NOD-SCID/IL2rgamma(null) mice. Curr. Top. Microbiol. Immunol. 2008, 324:87-94.
167. Wege A.K., Melkus M.W., Denton P.W., Estes J.D., Garcia J.V. Functional and phenotypic characterization of the humanized BLT mouse model. Curr. Top. Microbiol. Immunol. 2008, 324:149-165.
168. Reddy P., Negrin R., Hill G.R. Mouse models of bone marrow transplantation. Biol. Blood Marrow Transplant. 2008, 14:129-135.
169. Willinger T., Rongvaux A., Strowig T., Manz M.G., Flavell R.A. Improving human hemato-lymphoid-system mice by cytokine knock-in gene replacement. Trends Immunol. 2011, 32:321-327.
170. Stickler M., Valdes A.M., Gebel W., Razo O.J., Faravashi N., Chin R., Rochanayon N., Harding F.A. The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4(+) T-cell epitope in human interferon-beta. Genes Immun. 2004, 5:1-7.
171. Parker A.S., Zheng W., Griswold K.E., Bailey-Kellogg C. Optimization algorithms for functional deimmunization of therapeutic proteins. BMC Bioinforma. 2010, 11:180.
172. Cantor J.R., Yoo T.H., Dixit A., Iverson B.L., Forsthuber T.G., Georgiou G. Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:1272-1277.
173. Holgate R.G., Baker M.P. Circumventing immunogenicity in the development of therapeutic antibodies. IDrugs 2009, 12:233-237.
174. Jones T.D., Crompton L.J., Carr F.J., Baker M.P. Deimmunization of monoclonal antibodies. Methods Mol. Biol. 2009, 525:405-423. (xiv).
175. De Groot A.S., Goldberg M., Moise L., Martin W. Evolutionary deimmunization: an ancillary mechanism for self-tolerance?. Cell. Immunol. 2006, 244:148-153.
176. Warmerdam P.A., Plaisance S., Vanderlick K., Vandervoort P., Brepoels K., Collen D., De Maeyer M. Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling. Thromb. Haemost. 2002, 87:666-673.
177. De Groot A.S., Knopp P.M., Martin W. De-immunization of therapeutic proteins by T-cell epitope modification. Dev. Biol. (Basel) 2005, 122:171-194.
178. Scott D.W., De Groot A.S. Can we prevent immunogenicity of human protein drugs?. Ann. Rheum. Dis. 2010, 69(Suppl. 1):i72-i76.
179. Hellendoorn K., Jones T., Watkins J., Baker M., Hamilton A., Carr F. Limiting the risk of immunogenicity by identification and removal of T-cell epitopes (DeImmunisationTM). Cancer Cell Int. 2004, 4:S20.
180. Yeung V.P., Chang J., Miller J., Barnett C., Stickler M., Harding F.A. Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J. Immunol. 2004, 172:6658-6665.
181. Cobbold S.P., Qin S.X., Waldmann H. Reprogramming the immune system for tolerance with monoclonal antibodies. Semin. Immunol. 1990, 2:377-387.
182. Winsor-Hines D., Merrill C., O'Mahony M., Rao P.E., Cobbold S.P., Waldmann H., Ringler D.J., Ponath P.D. Induction of immunological tolerance/hyporesponsiveness in baboons with a nondepleting CD4 antibody. J. Immunol. 2004, 173:4715-4723.
183. Jordan S.C., Toyoda M., Vo A.A. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert. Rev. Clin. Immunol. 2011, 7:341-348.
184. Zandman-Goddard G., Krauthammer A., Levy Y., Langevitz P., Shoenfeld Y. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin. Rev. Allergy Immunol. 2012, 42(2):247-255.
185. Dykes A.C., Walker I.D., Lowe G.D., Tait R.C. Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2-year review. Haemophilia 2001, 7:160-163.
186. Provan D. Characteristics of immune thrombocytopenic purpura: a guide for clinical practice. Eur. J. Haematol. Suppl. 2009, 8-12.
187. Cines D.B., Liebman H., Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin. Hematol. 2009, 46:S2-S14.
188. Lozeron P., Adams D. Advances in the treatment of chronic inflammatory demyelinating neuropathies in 2010. J. Neurol. 2011, 258:1737-1741.
189. Mahdi-Rogers M., Rajabally Y.A. Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins. Biologics 2010, 4:45-49.
190. Mendelsohn N.J., Messinger Y.H., Rosenberg A.S., Kishnani P.S. Elimination of antibodies to recombinant enzyme in Pompe's disease. N. Engl. J. Med. 2009, 360:194-195.
191. Garman R.D., Munroe K., Richards S.M. Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease. Clin. Exp. Immunol. 2004, 137:496-502.
192. Su Y., Rossi R., De Groot A.S., Scott D.W. Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se. J. Leukoc. Biol. 2013, 94(2):377-383.
193. Cousens L.P., Su Y., McClaine E., Li X., Terry F., Smith R., Lee J., Martin W., Scott D.W., De Groot A.S. Application of IgG-derived natural Treg epitopes (IgG tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. J. Diabetes Res. 2013, 2013:621693.
194. Mingozzi F., High K.A. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 2013, 122(1):23-26.
195. van der Marel S., Majowicz A., Kwikkers K., van Logtenstein R., te Velde A.A., De Groot A.S., Meijer S.L., van Deventer S.J., Petry H., Hommes D.W., Ferreira V. Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis. World J. Gastroenterol. 2012, 18:4288-4299.
196. Mytych D.T., La S., Barger T., Ferbas J., Swanson S.J. The development and validation of a sensitive, dual-flow cell, SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin alfa and epoetin alfa in human serum. J. Pharm. Biomed. Anal. 2009, 49:415-426.
197. Wadhwa M., Thorpe R. Unwanted immunogenicity: lessons learned and future challenges. Bioanalysis 2010, 2:1073-1084.
198. Cruzado J.M., Bestard O., Grinyo J.M. New immunosuppressive protocols with the advent of novel biological drugs. Transplantation 2009, 88:S20-S23.
199. De Groot A.S., Tassone R., Cousens L.P., Terry F., Martin R., Ardito M., Martin W. In silico prediction of HLA-DP and ?DQ epitope content is poorly correlated with clinical immunogenicity of therapeutic proteins, manuscript in preparation (2013). Abstract presented at the American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference (NBC), San Diego, CA, USA. May 20-22 2013.